Lilly's orforglipron consistent with injectable GLP-1 medicines in Phase 3 trial

Apr 18, 2025

According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food...